【摘要】 目的探讨添加普拉克索治疗对帕金森病患者的统一帕金森病量表(UPDRS)评分及非运动症状的影响,同时观察治疗安全性。方法按照随机数字法分为对照组(71例)和观察组(74例),对照组患者给予复方左旋多巴治疗,观察组患者在使用复方左旋多巴的基础上添加普拉克索治疗,比较两组患者治疗前后UPDRSⅡ、Ⅲ评分及汉密尔顿抑郁量表(HAMD)及简易精神状态检查(MMSE)量表评分,比较两组患者的睡眠障碍,感觉异常,尿频尿急,便秘和流涎等非运动症状改善情况,及治疗后各种不良反应发生率。结果治疗后两组患者UPDRSⅡ、Ⅲ评分明显低于治疗前,且观察组显著优于对照组(P<0.05)。治疗后,观察组与对照组相比HAMD评分有明显降低(P<0.05),而MMSE评分无明显差异(P>0.05)。治疗后,两组患者睡眠障碍、感觉异常和尿频尿急的发生率有明显下降、且观察组低于对照组(P<0.05),而便秘和流涎的发生率无明显变化(P>0.05)。观察组患者的不良反应发生率为(9.46%),对照组患者的不良反应发生率为(16.90%),两组患者差异明显(P<0.05)。结论添加普拉克索治疗帕金森病的疗效明显,能提高PD患者的运动功能和日常生活能力,缓解忧郁、焦虑等不良情绪的发生,同时能有效改善患者的部分非部分运动症状,不良反应发生率较低。更多还原

【Abstract】 Objective To investigative the effect of adding pramipexole on the score of Unified Parkinson’s Disease Rating Scale( UPDRS) and non-motor symptoms of Parkinson’s disease,while observing the medication safety. Methods145 patients with Parkinson’s disease were randomly divided into observation group( 74 cases) and control group( 71 cases). The control group was treated with Madopar. The observation group was treated with Madopar and pramipexole. The therapy period was 16 weeks. Then the UPDRS Ⅱ、Ⅲ and numerous non-motor symptoms were evaluated in pretherapy and post-treatment,including Hamilton Depression Rating Scale( HAMD),Mini mental state examination( MMSE),sleep disturbances,sensory disturbances,micturition and urgent emiction,constipation and hydrostomia,while the incidence of adverse events after treatment were compared. Results After treatment,UPDRS Ⅱ,Ⅲ scores were significantly reduced in both the observation group and control group,however,the observation group was lower than the control group( P < 0. 05).HAMD scores were significantly decreased after treatment compared to pre-treatment in the observation( P < 0. 05). The differences of MMSE scores before and after treatment had not statistical significance( P > 0. 05). Parkinson’s disease associated sleep disturbances,sensory disturbances,micturition and urgent emiction improved significantly after treatment compared to those before the treatment,however,the improvement of the observation group was better than the control group( P< 0. 05). Nevertheless,constipation and hydrostomia did not improve largely,with no statistically significant differences( P> 0. 05). The total incidence of adverse reaction was 9. 46% in the observation group and 16. 90% in the control group( P< 0. 05). Conclusion The effect of adding pramipexole in the therapy of Parkinson’s disease is impressive,such as relief of depression and anxiety,noticeable improvement in part motor and non-motor symptoms,and a low incidence of adverse reactions,which is worthy of recommendation.更多还原